

## **Step Therapy Criteria**

<b>Step Therapy Group</b>	BENIGN PROSTATIC HYPERPLASIA
<b>Drug Names</b>	RAPAFLO
<b>Step Therapy Criteria</b>	Coverage will be provided if terazosin, alfuzosin, doxazosin or tamsulosin has been tried (at least a 30 day supply in the prior 180 days).
<b>Step Therapy Group</b>	BISPHOSPHONATES
<b>Drug Names</b>	FOSAMAX PLUS D
<b>Step Therapy Criteria</b>	Coverage will be provided if alendronate, ibandronate, or risedronate has been tried (at least a 30 day supply in the prior 180 days).
<b>Step Therapy Group</b>	GOUT
<b>Drug Names</b>	ULORIC
<b>Step Therapy Criteria</b>	Coverage will be provided if allopurinol has been tried (at least a 30-day supply in the prior 180 days)
<b>Step Therapy Group</b>	HMG-COA INHIBITORS
<b>Drug Names</b>	ALTOPREV, LIVALO, ZYPITAMAG
<b>Step Therapy Criteria</b>	Coverage will be provided if atorvastatin, ezetimibe/simvastatin, fluvastatin, fluvastatin extended-release, lovastatin, pravastatin, simvastatin tablets, rosuvastatin, or amlodipine/atorvastatin has been tried (at least a 30 day supply in the prior 180 days).
<b>Step Therapy Group</b>	URINARY ANTISPASMODICS
<b>Drug Names</b>	TOLTERODINE TARTRATE, TOLTERODINE TARTRATE ER
<b>Step Therapy Criteria</b>	Coverage will be provided if oxybutynin, oxybutynin extended-release, fesoterodine, solifenacin, trospium immediate-release, or mirabegron has been tried (at least a 30 day supply in the prior 180 days).